Access to Medicines
Public Citizen's Global Access to Medicines Program works with partners worldwide to improve health outcomes and save lives, through use of pharmaceutical cost-lowering measures including generic competition. We help civil society groups and public agencies overcome patent-based and other drug monopolies. Our work challenges Big Pharma's economic and political power.
Since the beginning of the millennium, generic competition has helped produce a global revolution in HIV/AIDS treatment. Competition has reduced the price of first-line antiretroviral (ARV) therapy by more than 99%, from more than $10,000 to well under $100 per person, per year. Cost reductions have enabled international agencies and government health programs to scale up treatment, providing lifesaving medicines to an estimated ten million people with HIV/AIDS in low- and middle-income countries today.
Major challenges remain. New cancer drugs are prohibitively expensive for all but the wealthy. Low- and middle-income countries confront rising rates of heart disease and other non-communicable diseases. Many of the biotech drugs needed to address these conditions will impose major burdens on healthcare budgets and are subject to emerging technical rules with long monopoly periods. Newer HIV/AIDS treatments are very expensive and widely patented, blocking the path to an AIDS-free generation. Hepatitis C infects perhaps 200 million people worldwide, largely in vulnerable populations – and the potential game-changing new treatment costs $1,000 per pill. And today’s models of pharmaceutical innovation still produce few advances for tropical diseases of the poor. Better public policy is possible.
Peter Maybarduk, Director
Peter Maybarduk directs Public Citizen's Global Access to Medicines Program, which helps developing countries overcome patent-based and other pharmaceutical monopolies in order to promote access to medicines for all. Maybarduk has provided in-depth and in person technical and strategic assistance to partners on every continent. His work has yielded major HIV/AIDS medicine price reductions, new state access to medicines policies, and global shifts toward anti-counterfeiting policies that safeguard generic competition. Maybarduk's analysis and advocacy have been instrumental in developing widespread opposition to measures in the proposed Trans-Pacific Partnership free trade agreement that would harm public interests including health and internet freedom.
Maybarduk studied law at the University of California at Berkeley and anthropology at the College of William and Mary in Virginia. He also directs International Professional Partnerships for Sierra Leone (IPPSL), a non-profit dedicated to supporting public sector development in one of the world's least developed countries. Maybarduk is a composer and performer of music. See: www.maybarduk.com
Burcu Kilic, Ph.D., Policy Adviser
Burcu Kilic is an expert on legal, economic and political issues surrounding intellectual property law, policy, development and innovation. She provides technical and legal assistance to governments and civil society groups around the world and promotes their participation in international rule making. She has performed research and written extensively on these subjects.
She completed her Ph.D. at Queen Mary, University of London as a School of Law Fellow, where she taught International and Comparative Patent Law and Policy. She holds Masters degrees from University of London and Stockholm University in Intellectual Property Law and Law and Information Technology and a law degree from Ankara University. She is also a SARChI Research Fellow at Institute for Economic Research on Innovation, Tshwane University of Technology, South Africa.
Back to Access to Medicines Home Page